Producción CyT
Artículo
Autoría
Aguirre, Florencia
;
Justo, Mariano Ezequiel
;
Cialdella, Lucía
;
PAZ, MARIELA LAURA
Fecha
2024
Editorial y Lugar de Edición
SPRINGER
Revista
NEUROLOGICAL SCIENCES,
vol. 46
(pp. 1827-1832)
- ISSN 1590-1874
SPRINGER
SPRINGER
ISSN
1590-1874
Resumen
Información suministrada por el agente en
SIGEVA
Background: Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies (abs) targeting proteinsat the neuromuscular junction, primarily the acetylcholine receptor (AChR). While the role of AChR-binding abs is well-established, the pathogenicity and clinical relevance of AChR-blocking antibodies in MG, and their association with com-plement system, remain less understood. Aims: This study aims to provide comprehensive insights into the prevalence and interplay of AChR-block...
Background: Myasthenia gravis (MG) is an autoimmune disorder characterised by autoantibodies (abs) targeting proteinsat the neuromuscular junction, primarily the acetylcholine receptor (AChR). While the role of AChR-binding abs is well-established, the pathogenicity and clinical relevance of AChR-blocking antibodies in MG, and their association with com-plement system, remain less understood. Aims: This study aims to provide comprehensive insights into the prevalence and interplay of AChR-blocking antibodies andthe complement system in an Argentinian MG cohort, investigating their relationships with disease activity.Methods: We studied 75 MG patients with detectable AChR-binding abs, assessing the presence of AChR-blocking abs andcomplement components C3, C4, and C5a. We also examined clinical severity using the Activities of Daily Living and MGComposite scores. Correlation analyses were made to elucidate associations.Results: AChR-blocking abs were detected in 49.3% of the patients. An inverse correlation was found between AChR-blockingabs titres and disease severity, with a higher titre associated with milder symptoms. Complement analysis revealed higherC4 levels in the AChR-blocking abs positive group, indicating reduced complement activation. Conclusion: Our study provides valuable insights into the prevalence of AChR-blocking antibodies. Higher AChR-blockingabs titres were associated with less severe MG and reduced complement system activation, indicating a potential protectivemechanism for those abs. These fndings suggest that AChR-blocking abs could serve as a potential biomarker for a milderdisease course and highlight the need for further research to understand their role in MG pathology, which will improvestrategies for clinical management and diagnosis.
Ver más
Ver menos
Palabras Clave
Complement systemAChR-blocking antibodiesMyasthenia gravisAChR-binding
Descargue o solicite el texto completo